RESCAP: REScuing Alkaline Phosphatase, is an endogenous enzyme that can prevent ischemia-reperfusion damage following invasive surgery.

What is RESCAP®?

Alkalyne phophatase

Alloksys Life Sciences developed the therapeutic RESCAP® platform based on Alkaline Phosphatase (AP), a naturally occurring protein in the human body. 

RESCAP® is capable of preventing adverse downstream complications like tissue damage, systemic inflammations and organ failure during and after major surgery.

No adverse side effect has been observed in trials so far.


How does RESCAP® work?

RESCAP® works as prophylactic and therapeutic anti-inflammatory protein that prevents and treats ischemic injury.

RESCAP® prevents ischemic injury by neutralising and detoxifying inflammatory triggers that may derail the immune system. These triggers include danger signals (e.g. ATP released from tissue during surgery) and stranger signals (e.g. bacterial LPS entering body). This results in general protection of tissues and organs. 

RESCAP® further protects, maintains and restores integrity of physiological barriers, such as Kidney Glomerulus Barrier (KGB) Blood Brain Barrier(BBB), Lung Alveolar Barrier(LAB), Gut Barrier (GB) and Placental Barrier (PB).

Finally, RESCAP® facilitates transport of nutrients and trophins across barriers.


What are the Effects of RESCAP®?

Among the most beneficial charachteristics of RESCAP® are the fast onset of action and quick clearance from the body. In acute settings RESCAP® triggers enhanced endogenous production of AP by the body thereby boosting innate defence systems. 

RESCAP® also has potential applications in the prevention and curing of chronic inflammatory diseases such as Rheumatoid Arthritis, Cystic Fibrosis, Diabetes and neuro-degenerative diseases. Those opportunities are exploited by sister company AMRIF.


bRESCAP®

bRESCAP® is based on calf intestine from BSE free countries. It has a fast onset of action, a high dosing efficacy and a short residence time in the body (half life of a few minutes), which makes bRESCAP® ideal for acute clinical disorder treatments.

Currently Alloksys is focused on the Ph lll trial of bRESCAP® in open heart surgery. During the next stage further major surgery applications will be developed.

hRESCAP®

Alloksys’ proprietary human recombinant RESCAP® is produced on Alloksys' proprietary CAP-9 cell platform. It has a longer residence period in the body, a half life of 6 days, making it specifically suited for longer term treatments of chronic diseases. 

Sister company AMRIF develops treatments for chronic inflammatory diseases based on hRESCAP®.


References

Overview of Alkaline Phosphatase activities: Lalles et al., 2014

Overview of the role of Alkaline Phosphatase in clinical diseases: Fawley et al., 2016 

Kats et al., Prophylactic treatment with alkaline phosphatase in cardiac surgery induces endogenous alkaline phosphatase release. Int. J. Artificial Organs 2012; 35 (2): 144-151

Pike et al., A novel hypothesis for an alkaline phosphatase 'rescue' mechanism in the hepatic acute phase immune response. Biochim Biophys Acta. 2013 Dec;1832(12):2044-56

Fiechter et al. Bovine intestinal alkaline phosphatase reduces inflammation after induction of acute myocardial infarction in mice. Cardiology Research 2011; 2(5):236-242

Kats et al. Endotoxin release in cardiac surgery with cardiopulmonary bypass: pathophysiology and possible therapeutic strategies. An update. Eur J Cardiothorac Surg. 2011; Apr; 39(4):451-8